Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever |
| |
Authors: | O A Cornely U Bethe B Salzberger C Franzen P Hartmann T Steinmetz G Fätkenheuer H Seifert V Diehl M Schrappe |
| |
Institution: | (1) Department of Internal Medicine I, University Hospital of Cologne, 50924 Cologne, Germany e-mail: oliver.cornely@uni-koeln.de Tel.: +49-221-4784431 Fax: +49-221-4785956, DE;(2) Institute for Medical Microbiology and Hygiene, University Hospital of Cologne, 50924 Cologne, Germany, DE;(3) Quality Management of the University Hospital of Cologne, 50924 Cologne, Germany, DE |
| |
Abstract: | A prospective, randomized, controlled monocentric trial was performed to evaluate the efficacy and safety of once daily ceftriaxone
2 g plus tobramycin 5 mg/kg in comparison to cefotaxime 2 g t.i.d. plus tobramycin 5 mg/kg qd in the treatment of neutropenic
fever. In cases of fever ≥38.5 °C and a neutrophil count below 1000/μl, patients with hematological malignancies were assigned
to ceftriaxone or cefotaxime, each with tobramycin. The primary endpoint was defined as defervescence <37.5 °C on day 4–6
followed by at least 7 afebrile days. Secondary endpoints were overall response, defined as defervescence on day 25 and toxicity.
There were 160 episodes of 114 patients included. Fever of unknown origin accounted for 79 episodes (51%), microbiologically
defined infection for 36 (23%), clinically defined infection for 27 (17%), and both clinically and microbiologically defined
infection for 14 episodes (9%). On an intent-to-treat basis 156 episodes could be evaluated for the primary endpoint. Ceftriaxone
plus tobramycin and cefotaxime plus tobramycin resulted in a primary response in 46.9% and 45.3%, respectively. Overall response
was achieved on study day 25 in 87.7% and 80%, respectively. No significant difference in toxicity was observed. Once-daily
ceftriaxone plus tobramycin was not inferior to cefotaxime t.i.d. plus tobramycin qd in the empirical treatment of neutropenic
fever.
Received: 29 October 1999 / Accepted: 28 August 2000 |
| |
Keywords: | Neutropenia Granulocytopenia Fever Ceftriaxone Cefotaxime |
本文献已被 PubMed SpringerLink 等数据库收录! |
|